Cont. from page xxx.

- Subsequent options for CHL:
 - ▶ Bendamustine + carboplatin + etoposide was added, with corresponding footnote: Budde LE, Wu D, Martin DB, et al. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. *Br J Haematol* 2018;183:601-607.
 - ▶ GEMOX (gemcitabine, oxaliplatin) was added, with corresponding footnote: Gutierrez A, Rodriguez J, Martinez-Serra J, et al. Gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. *Onco Targets Ther* 2014;7:2093-2100.
 - ▶ C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) was changed from a category 2B to a category 2A recommendation.
- Footnote "c" was added.
- Reference 25 (for pembrolizumab) was updated: Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. *J Clin Oncol* 2017;35(19):2125-2132.

HODG-F (1 of 2)

- Brentuximab vedotin followed by AVD conditionally followed by brentuximab vedotin in responding patients with CR or PR was added to options for stage I-II unfavorable or stage III-IV disease, for older adults (age >60), with corresponding footnote: Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. *J Clin Oncol* 2018;36:3015-3022.

Erratum

Erratum to: Cutler and Pavletic. NCCN Guidelines: Pretransplant Recipient Evaluation and Management of Graft-Versus-Host Disease. *J Natl Compr Canc Netw* 2020;18(5):645–647.

In the May issue of *JNCCN—Journal of the National Comprehensive Cancer Network*, the doi for the article, "NCCN Guidelines: Pretransplant Recipient Evaluation and Management of Graft-Vs-Host Disease," by Cutler and Pavletic (pages 645–647) was printed incorrectly. The correct doi is 10.6004/jnccn.2020.7575.

This has been corrected online at [JNCCN.org](https://www.jnccn.org). The editorial office apologizes for the error.

doi: 10.6004/jnccn.2020.2001